Brief: Shuttle Pharmaceuticals Submits IND Application To The US FDA For Ropidoxuridine Phase II Clinical Trial For Patients With Glioblastoma

Shuttle Pharmaceuticals Holdings

11/12/2023 14:19

Dec 11 (Reuters) - Shuttle Pharmaceuticals Holdings Inc
 SHPH.O :
    * SHUTTLE PHARMACEUTICALS SUBMITS IND APPLICATION TO THE
U.S. FDA
FOR ROPIDOXURIDINE PHASE II CLINICAL TRIAL FOR PATIENTS WITH
GLIOBLASTOMA

Source text for Eikon:  ID:nPn1rTZ0Sa 
Further company coverage:  SHPH.O 

 ((Reuters.Briefs@thomsonreuters.com;))